Other News To Note
Thursday, July 14, 2011
OncoVista Innovative Therapies Inc., of San Antonio, initiated a preclinical safety study of OVI-117, an L-Nucleoside conjugate for solid tumors, in a second animal species. The company also is preparing to submit an investigational new drug application and plans to begin Phase I trials by the end of the year.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.